SupremeToday Landscape Ad
Back
Next
Judicial Analysis Court Copy Headnote Facts Arguments Court observation
Listen Audio Icon Pause Audio Icon
judgment-img

2020 Supreme(Del) 663

IN THE HIGH COURT OF DELHI AT NEW DELHI
Jayant Nath, J.
Sun Pharma Laboratories Limited - Appellant
Versus
Bdr Pharmaceuticals International Pvt. Ltd. & Anr. - Respondent
Civil Suit (Comm) No. 757 of 2017
Decided On : 05-06-2020

Advocates Appeared:
Hemant Singh, Advocate, Mamta Jha, Advocate, Wasee Shuaib Ahmed, Advocate, Tahir A J, Advocate, Dayan Krishnan, Advocate, Rishi Agarwala, Advocate, Niyati Kohlim, Advocate, Pranjit Bhattacharya, Advocate, Megha Bengani, Advocate, Akashi Lodha, Advocate, Sanjeevi Sheshadri, Advocate

The judgment established the principle that a stricter approach is required for medicinal products in cases of trademark infringement, considering the potential adverse consequences on health and life. The court also emphasized that mere delay in bringing action is not sufficient to defeat the grant of injunction in cases of trademark infringement.

Headnote:

Infringement - Trademark - Sections 28, 29(1) - The court granted a decree of permanent injunction in favor of the plaintiff, restraining the defendant from using the trademark LULIBET or any similar mark, as it was found to be deceptively similar to the plaintiff's trademark LABEBET. The court considered the phonetic, visual, and structural similarity of the marks and the stricter approach required for medicinal products.

Fact of the Case:

The plaintiff sought a permanent injunction to restrain the defendants from using the trademark LULIBET, which was found to be deceptively similar to the plaintiff's trademark LABEBET. The plaintiff argued that the defendants' use of the mark constituted infringement of the plaintiff's trademark under section 29 of the Trade Marks Act, 1999.

Finding of the Court:

The court found that the trademark LULIBET was deceptively similar to the plaintiff's trademark LABEBET, and the use of the mark by the defendant constituted infringement under section 29(1) of the Act. The court also considered the stricter approach required for medicinal products.

Issues: The main issue was whether the defendant's use of the trademark LULIBET constituted infringement of the plaintiff's trademark LABEBET under section 29(1) of the Trade Marks Act, 1999.

Ratio Decidendi: The court held that the trademark LULIBET was deceptively similar to the plaintiff's trademark LABEBET, and the use of the mark by the defendant constituted infringement under section 29(1) of the Act. The court also emphasized the stricter approach required for medicinal products.

Final Decision: The court granted a decree of permanent injunction in favor of the plaintiff, restraining the defendant from using the trademark LULIBET or any similar mark. The decree of permanent injunction would be effective after two months from the date of the judgment.

JUDGMENT

Jayant Nath, J. - This suit is filed by the plaintiff seeking a decree of permanent injunction to restrain the defendants etc. from manufacturing, marketing, selling, offering for sale, advertising, directly or indirectly dealing in medicinal preparations under the impugned mark LULIBET or any other mark that may be visually, structurally or phonetically deceptively similar to the plaintiff''s trademark LABEBET amounting to infringement of registered trademark of the plaintiff. Other connected reliefs are also sought.

2. The above matter came up for hearing on 4.1.2018 when the court passed the following order:-

"Written statement of the defendant no.1 is taken on record.

The suit is listed for framing of issues if any and for hearing of the application for interim relief.

The counsel for the plaintiff and the senior counsel for the defendant no. 2 have been heard.

The counsel for defendant No.1 adopts the arguments of the senior counsel for defendant No.2.

The plaintiff has sued inter alia for permanent injunction restraining infringement of trade mark and passing off in relation to its medicinal preparation "LABEBET" by the defendants by adoption of the mark "LULIBET", also for medicinal preparation.

There is no interim injunction till now.

The counsel for the plaintiff on enquiry states that while the medicine of the plaintiff is for the ailment of hypertension and is marketed in tablet and injection form, the medicine of the defendants is for the ailment of fungal infection and marketed in ointment and spray form.

The senior counsel for the defendant No.2 on enquiry, states that the defendant No.2 is manufacturing the medicine "LULIBET" and the defendant No.1 is marketing the same.

I have enquired from the counsel for the plaintiff whether not in the aforesaid circumstances, there is no possibility of confusion and deception since the two medicines are for different ailments and since, to my knowledge, there is no medicine available in the form of ointment or spray for the ailment of hypertension.

The counsel for the plaintiff has argued (i) that the registration of the mark of the plaintiff is in Class-V and relating to pharmaceutical and medicinal preparations in general and not for the pharmaceutical preparation for the ailment of hypertension only; (ii) that thus Section 29(i) will apply; (iii) that the possibility of patients with the ailment of fungal infection consuming the tablet or being treated with an injection of the product of the plaintiff exists inasmuch as for such ailments medicines in tablet and injection form are also available; and (iv) reliance is placed on Cadila Health Care Ltd. Vs. Cadila Pharmaceuticals Ltd., (2001) AIR SC 1952 .

Per contra, the senior counsel for the defendants No.2 has (i) drawn attention to page 42 of the plaintiff''s documents to show that the molecule of the medicine of the plaintiff "Labetalol Hydrochloride IP 100 mg" and to page 6 of the defendants'' documents to show that the molecule of the medicine of the defendants is "Luliconazole"; (ii) has drawn attention to page 52 of the Part-I file to show that for fungal infection, large number of other medicines with the molecule name "Luliconazole" are available; (iii) has relied on M/s. Panacea Biotee Ltd. Vs. M/s. Recon Ltd., (1997) AIR Delhi 244 ; and, (iv) has contended that the plaintiff in the plaint has admitted that the defendants also have applied for registration and has not opposed the application and is thus not entitled to injunction.

On enquiry, the counsel for the plaintiff states that the Registrar of Trade Marks does not have power to entertain an objection after the time prescribed for filing objection of four months from the date of advertisement and the only remedy of a person who has so missed the opportunity is to apply the cancellation of the registration if any granted.

I have during the hearing informed the counsels that considering the nature of the controversy, the suit, insofar as for the reli

Click Here to Read the rest of this document
1
2
3
4
5
6
7
8
9
10
11
Judicial Analysis

AI

SupremeToday Portrait Ad
supreme today icon
logo-black

An indispensable Tool for Legal Professionals, Endorsed by Various High Court and Judicial Officers

Please visit our Training & Support
Center or Contact Us for assistance

qr

Scan Me!

India’s Legal research and Law Firm App, Download now!

For Daily Legal Updates, Join us on :

whatsapp-icon Back to top